The NanoMedicines Innovation Network (NMIN), a national research network funded by …
Previous
Next
Latest news...
Since news of the Pfizer-BioNTech COVID-19 vaccine first broke in November …
Three-minute knowledge translation videos created by NMIN HQP Dr. Shahla Shojaei …
L to R: Drs. Robert Hancock, Edward Sargent, Pieter Cullis, John …
Two new publications highlight recent research from the UBC-based lab of …
“Canada’s biomedical community can clearly be competitive globally. However, we need …
Two NMIN researchers were recently recognized with awards from the Controlled …
Edmonton-based company Entos Pharmaceuticals has developed a new DNA-based vaccine for …
NMIN is pleased to announce the launch of three interactive, online …
Dr. Cullis stepping down as Scientific Director to pursue commercialization opportunities …
In a January 15, 2021 seminar organized by the Life Sciences …
In a review article published today in Advanced Healthcare Materials, NMIN …
Three reviews by NMIN researchers – Drs Pieter Cullis, Shana Kelley, …
https://youtu.be/M-NUP8Xs9-g Above: watch the 26 April 2021 coverage of this story …
A new article by NMIN researchers published in the journal Nanoscale …
On September 17, 2020, Vancouver Nanomedicine Day was delivered for the …
NMIN
about us
Advancing research, innovation and training in nanomedicines to maintain Canada as the world leader in the field.
The NanoMedicines Innovation Network (NMIN) is advancing “smart” medicines to cure disease by delivering small molecule drugs more specifically to disease sites and enabling the clinical use of gene therapies.
NMIN brings Principal Investigators from institutions across Canada together with companies and not-for-profit research and granting institutions in a network committed to expanding and improving Canada’s position as a global leader in nanomedicines R&D.
NMIN is funded by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.
NMIN
Our focus
Develop nanomedicines
that enhance the therapeutic properties of small molecule drugs, and enable gene therapies.
Develop new diagnostics
that enable more precise disease detection and treatment, based on nanotechnology.
Train scientists
in the technology and business of nanomedicines, guided by market needs for HQP with skills required by the R&D community.
Translate nanomedicine
products and technologies, by implementing a cohesive IP and commercialization strategy.
NMIN
Management Team
Pieter Cullis
Scientific Director
Gilbert Walker
Associate Scientific Director
Diana Royce
Executive Director
NMIN
Contact
NMIN
2350 Health Sciences Mall, Room 5451 | University of British Columbia | Vancouver, BC V6T 1Z3 Canada
NMIN
2350 Health Sciences Mall, Room 5451 | University of British Columbia | Vancouver, BC V6T 1Z3 Canada
info@nanomedicines.ca